
Dermatology Times December 2024 Recap
Key Takeaways
- Yesintek, a Stelara biosimilar, gains FDA approval for psoriasis and psoriatic arthritis, with a 2025 launch anticipated.
- Delgocitinib significantly reduces inflammation in chronic hand eczema, acting as a topical pan-JAK inhibitor.
Dermatology Times is looking back on the top stories in dermatology from the month of December.
Clearances, Approvals, Updates, and Recommendations
The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.
Big Studies and Big Data
Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.
The algorithm demonstrated 81% accuracy, promising fast, reliable, and reproducible assessments for patients.
Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.
The adalimumab biosimilar had an average persistence of 2.5 years, according to this British study.
Market and Pharma News, Drug Watch
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.
The exclusive event brought together physician assistants and nurse practitioners from across the country to review atopic dermatitis and psoriasis patient cases.
Strides for Skin Health Equity
Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.
Researchers noted higher correlations in those who are prone to severe acne and post acne erythema (PAE).
The effect of insurance status on US patients with psoriasis can help identify those at risk of being undertreated.
Don’t miss a moment of Dermatology Times by signing up for our
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















